Alterity Therapeutics Limited (NASDAQ:ATHE) Sees Significant Increase in Short Interest

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 167,300 shares, an increase of 12.6% from the December 15th total of 148,600 shares. Approximately 2.0% of the shares of the stock are short sold. Based on an average daily volume of 64,600 shares, the days-to-cover ratio is presently 2.6 days.

Alterity Therapeutics Trading Up 1.8 %

ATHE stock opened at $3.42 on Friday. The company’s 50 day simple moving average is $2.30 and its 200-day simple moving average is $1.72. Alterity Therapeutics has a 12 month low of $1.00 and a 12 month high of $4.71.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC grew its stake in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,883 shares of the company’s stock after acquiring an additional 8,100 shares during the quarter. HB Wealth Management LLC owned about 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent quarter. 2.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Maxim Group started coverage on Alterity Therapeutics in a research note on Thursday, December 12th. They set a “buy” rating and a $8.00 price target for the company.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.